Repros Therapeutics Inc. (NASDAQ:RPRX) was up 4.3% during trading on Friday . The stock traded as high as $2.25 and last traded at $2.20, with a volume of 307,980 shares. The stock had previously closed at $2.11.

Separately, Zacks Investment Research downgraded shares of Repros Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the stock. Repros Therapeutics has a consensus rating of “Hold” and a consensus target price of $21.50.

The stock’s 50-day moving average price is $1.76 and its 200-day moving average price is $1.55. The firm’s market capitalization is $53.01 million.

Repros Therapeutics (NASDAQ:RPRX) last released its earnings results on Tuesday, May 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.02. Analysts anticipate that Repros Therapeutics Inc. will post ($0.75) EPS for the current fiscal year.

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.